Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Artificial intelligence (AI) is now making waves in the pharmaceutical and life sciences industry. Healthcare leaders are now dealing with the question: How can AI make patient outcomes better without losing sight of the people it’s designed to serve?
O’Reilly draws from her experience as a pharmacist, her studies in neuroscience, digital health and healthcare system innovation. She tells Dua that healthcare needs a foundational mindset shift. Particularly, the industry is encouraged to move to patient-first rather than technology-forward. This means keeping technology as a secondary step to ensuring deeper, more structural patient inclusion.
“Patients really need to have a permanent seat at the decision-making table,” O’Reilly stated, alluding to the fact that healthcare innovation should be anchored in the experiences of the people it ultimately serves.
The former pharmacist believes that technology solely will not determine if healthcare innovations are successful. The vision O’Reilly depicts is of patients becoming active participants across the end-to-end care journey, rather than passive recipients.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
Why is Patient Inclusion Key to Successful Innovation in Pharma?
“Patient-centricity” is evidently one of the most used terms in healthcare and pharma over the past decade. However, according to O’Reilly, patient inclusion continues to evolve and remains one of the greatest enablers to the development of successful innovation.
Healthcare requires a systemic change that puts patients at the centre of the decision-making process, O’Reilly discusses. By virtue of living with their conditions, they are experts in their own care and the only individuals involved in every single decision made along the end-to-end care journey. They hold critical insights about their care needs that may not be visible to clinicians or researchers. This is spotlighted as the “missing data,” O’Reilly explains, which can change the trajectory of outcomes using technology.
Instead of bringing lists of symptoms, patients can now bring clinicians' recommendations, summaries and individualised health insights, with the advent of AI platforms like ChatGPT. However, the real opportunity for AI lies in how patients communicate with their clinical teams, O’Reilly believes.
One example of this is its potential role in shared decision-making, an important component of “patient-centred care”, she explains.
In this context, there is a potential role for AI when it comes to better informing patients and supporting them in taking a more active role in their care journeys, and also for clinicians when it comes to preparing medical information in a format that is more “patient-oriented”. However, AI will not replace clinicians, O’Reilly asserts. AI is an augmentation tool: “It's not a substitute for medical expertise,” she explained.
Healthcare Transformation Partner at Roche illustrates favourable outcomes for patient-first technologies.
One of the greatest values of digital innovation is its capacity for continuous data collection. Conditions like MS often involve symptom fluctuations over time. This means that isolated appointments often only capture a discrete snapshot of the patient's experience at a particular moment in time. Continuous data collection can help create a more accurate and nuanced understanding of patients' well-being.
As excitement for AI grows in healthcare, organisations risk getting distracted by the technology itself. Instead, O’Reilly calls for “needs-led” innovation, which involves rigorous, evidence-based assessment of the problem being solved for.
As she summarised, "We need to fall in love with the problem" in healthcare; creating great solutions means little if the initial problem was misunderstood.
True patient engagement ensures patients have a permanent seat at the decision-making table
When it comes to advancing patient-centred healthcare, some of the greatest potential for AI lies in its capacity to transform how clinicians and patients communicate, and how patients engage in decisions about their care
Healthcare transformation should be underpinned by a “needs-led”, rather than solution-driven approach; otherwise we risk building brilliant solutions for problems that may not exist.
The user experience of the clinician cannot be ignored. Innovation only moves as fast as clinical adoption. Their readiness to embrace new tools is the bridge to patient impact.
Chapters
00:00 Introduction to Healthcare Transformation
03:49 The Role of Patient Engagement
08:50 AI's Impact on Patient-Provider Communication
12:49 Operationalising Patient Engagement
14:12 AI and Digital Health Innovations
18:31 Collaborative Initiatives in Healthcare
20:48 Future of Pharma and Patient Interaction
22:46 Integrating Real-World Insights
25:26 Patient-Centric Clinical Studies
27:28 Key Takeaways for Pharma Leaders
Coming soon
Ask questions about this interview.
AI Assistant will use the video transcript once it is available.
A B2B journalist, Podcast Host and Producer with a PPA-accredited MA in Magazine Journalism from Cardiff University. Specialising in content strategy and execution for segments on healthcare technology, AI, emerging innovation, and life sciences at Pharmatica.io. Bringing lively, up-to-date conversations to life on camera. Hosted and produced enterprise podcasts for global technology enterprises, covered CES 2024, Infosec 2025 and 2026 and Big Data LDN 2025 and 206 live by hosting vox pop interviews on camera. Also, written for publications including Interesting Engineering and The Hindu.
Did you enjoy the content?
0
Why not support
Shubhangi Dua
by giving this content a like
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
Success for Non-Animal Testing of Preclinical Toxicity?
Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.
Good Laboratory Practice Always Sets the R&D Standard
Good Laboratory Practice strengthens data integrity, reproducibility, and regulatory confidence across pharma non-clinical R&D and preclinical research.
Seven Ways AI Is Solving Pharmaceutical Supply Chain Problems
AI is tackling the pharmaceutical supply chain's most persistent problems, from demand forecasting to counterfeit detection. See the top 7 ways AI is improving supply chain resiliency.
Comments (0)